Literature DB >> 15130953

Hypoxic tissue in ischaemic stroke: persistence and clinical consequences of spontaneous survival.

R Markus1, D C Reutens, S Kazui, S Read, P Wright, D C Pearce, H J Tochon-Danguy, J I Sachinidis, G A Donnan.   

Abstract

In ischaemic stroke, expansion of the infarct core occurs at the expense of surrounding hypoxic, metabolically compromised tissue over a period of 24 h or more in a considerable proportion of patients. It is uncertain whether hypoxic tissue observed at later times after stroke onset retains the potential for survival or whether such survival has an impact on functional outcome. These factors may determine the effectiveness of therapeutic strategies aimed at salvaging this tissue. We tested the hypotheses that metabolically compromised hypoxic tissue observed within 48 h after onset of ischaemic stroke retains the potential for spontaneous survival and that the impact of such survival on functional outcome is time dependent. Consecutive patients presenting within 48 h of ischaemic stroke were studied with [(18)F]fluoromisonidazole, a ligand binding to hypoxic but viable tissue, and PET. Subjects were grouped into two time epochs, </=12 and >12 h, based on the interval from stroke onset to the time of tracer injection, and had infarct volumes measured on CT/MRI at 7 days (n = 60). The total ischaemic volume (TIV) and the proportion of the TIV that spontaneously survived (surviving hypoxic volume ratio, SHVR) were defined from the co-registered CT/MRI images. These volumetric measures were correlated with neurological outcome assessed at day 7-10 by percentage change in the National Institutes of Health Stroke Scale (DeltaNIHSS), and at 3 months by Barthel Index (BI) and modified Rankin Score (mRS). Of 66 patients investigated, hypoxic tissue occurred in 33 and outcome data was available in 27. Hypoxic tissue constituted >20% of the TIV in 60% of studies </=12 h and 16% >12 h. The spontaneously surviving proportion of the TIV (median 6.9%) or hypoxic tissue (median 45.9%) was not significantly different in patient subgroups studied </=12 or >12 h after stroke onset. Spontaneous survival of hypoxic tissue (surviving hypoxic volume ratio) was associated with improved neurological outcome in both time epochs: </=12 h, DeltaNIHSS (r = 0.85, P < 0.01), day 90 BI (r = 0.86, P < 0.01) and day 90 mRS (r = -0.89, P < 0.01); >12 h, DeltaNIHSS (r = 0.59, P < 0.01) and day 90 mRS (r = -0.46, P < 0.05). The finding that similar proportions of hypoxic tissue survived spontaneously within each time epoch suggests that its fate is not predetermined. The favourable neurological outcome associated with spontaneous survival of hypoxic tissue, even 12-48 h after stroke onset, suggests that the volume of hypoxic tissue that progressed to infarction may represent a valuable target for therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15130953     DOI: 10.1093/brain/awh162

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  38 in total

1.  PET Detection of Cerebral Necrosis Using an Infarct-Avid Agent 2-Deoxy-2-[18F]Fluoro-D-Glucaric Acid (FGA) in a Mouse Model of the Brain Stroke.

Authors:  Hailey Houson; Alexander Mdzinarishvili; Hariprasad Gali; Evgeny Sidorov; Vibhudutta Awasthi
Journal:  Mol Imaging Biol       Date:  2020-10       Impact factor: 3.488

Review 2.  Neuroimaging of ischemia and infarction.

Authors:  Erica C Sá de Camargo; Walter J Koroshetz
Journal:  NeuroRx       Date:  2005-04

3.  Feasibility of 62Cu-ATSM PET for evaluation of brain ischaemia and misery perfusion in patients with cerebrovascular disease.

Authors:  Makoto Isozaki; Yasushi Kiyono; Yoshikazu Arai; Takashi Kudo; Tetsuya Mori; Rikiya Maruyama; Ken-ichiro Kikuta; Hidehiko Okazawa
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-02-02       Impact factor: 9.236

4.  'Salvaged' stroke ischaemic penumbra shows significant injury: studies with the hypoxia tracer FMISO.

Authors:  Neil J Spratt; Geoffrey A Donnan; Damian D McLeod; David W Howells
Journal:  J Cereb Blood Flow Metab       Date:  2010-09-29       Impact factor: 6.200

Review 5.  Brain-mapping techniques for evaluating poststroke recovery and rehabilitation: a review.

Authors:  James C Eliassen; Erin L Boespflug; Martine Lamy; Jane Allendorfer; Wen-Jang Chu; Jerzy P Szaflarski
Journal:  Top Stroke Rehabil       Date:  2008 Sep-Oct       Impact factor: 2.119

6.  Association between the perfusion/diffusion and diffusion/FLAIR mismatch: data from the AXIS2 trial.

Authors:  Anke Wouters; Patrick Dupont; Erich B Ringelstein; Bo Norrving; Angel Chamorro; Martin Grond; Rico Laage; Armin Schneider; Guido Wilms; Götz Thomalla; Robin Lemmens; Vincent N Thijs
Journal:  J Cereb Blood Flow Metab       Date:  2015-06-03       Impact factor: 6.200

Review 7.  How to make better use of thrombolytic therapy in acute ischemic stroke.

Authors:  Geoffrey A Donnan; Stephen M Davis; Mark W Parsons; Henry Ma; Helen M Dewey; David W Howells
Journal:  Nat Rev Neurol       Date:  2011-06-14       Impact factor: 42.937

Review 8.  Imaging the physiological evolution of the ischemic penumbra in acute ischemic stroke.

Authors:  Richard Leigh; Linda Knutsson; Jinyuan Zhou; Peter Cm van Zijl
Journal:  J Cereb Blood Flow Metab       Date:  2017-03-27       Impact factor: 6.200

9.  Imaging of hypoxic-ischemic penumbra with (18)F-fluoromisonidazole PET/CT and measurement of related cerebral metabolism in aneurysmal subarachnoid hemorrhage.

Authors:  Asita S Sarrafzadeh; Alexandra Nagel; Marcus Czabanka; Timm Denecke; Peter Vajkoczy; Michail Plotkin
Journal:  J Cereb Blood Flow Metab       Date:  2009-09-23       Impact factor: 6.200

10.  Multivariate dynamic prediction of ischemic infarction and tissue salvage as a function of time and degree of recanalization.

Authors:  André Kemmling; Fabian Flottmann; Nils Daniel Forkert; Jens Minnerup; Walter Heindel; Goetz Thomalla; Bernd Eckert; Michael Knauth; Marios Psychogios; Soenke Langner; Jens Fiehler
Journal:  J Cereb Blood Flow Metab       Date:  2015-07-08       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.